The memorandum is available on the Clines website (www.clinescientific.com/foretradesemission-2022).

The application form for subscription without the support of subscription rights can be obtained from Nordic Issuing's platform (www.nordic-issuing.se) from the first day of the subscription period (14 November 2022).

About the Rights Issue

The Board of Directors of Cline resolved on November 2, 2022, with the support of the authorization from the Annual General Meeting on April 20, 2022, to carry out the Rights Issue of a maximum of 15,452,737 shares, divided into a maximum of 722,333 A shares and a maximum of 14,730,404 B shares. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 17 million, before deduction of issue costs, which are estimated to amount to approximately SEK 1.6 million. The proceeds from the Rights Issue are primarily intended to be used to enable continued operation and continued development of the two projects CellRACE and StemCART.

• Trading in subscription rights: November 14 - November 23, 2022
• Subscription period: November 14 -November 28, 2022
• Announcement of outcome: around December 1, 2022
• Trading in BTA: trading in BTA (paid subscribed share) will take place from and including 14 November 2022 until the Rights Issue is registered with the Swedish Companies Registration Office, which is expected to take place around mid-December 2022

• The subscription price in the Rights Issue amounts to SEK 1.10 per share regardless of share type.

• The Rights Issue comprises a maximum of 15,452,737 shares divided into a maximum of 722,333 class A shares and a maximum of 14,730,404 class B shares. Upon full subscription in the Rights Issue, Cline will receive approximately SEK 17 million before issue costs.

• In case of full subscription in the Rights Issue, the Company will receive approximately SEK 17 million, before deductions for issue costs, which are estimated to amount to approximately SEK 1.6 million.
• Shareholders in the Company who, on November 10, 2022, was registered in the share register maintained by Euroclear Sweden AB has preferential rights to subscribe for new shares in the Rights Issue. For each existing A share, one (1) subscription right of series A was obtained, and for each existing B share, one (1) subscription right of series B was obtained. One (1) subscription right of series A entitles to subscription of one (1) new A share, and one (1) series B subscription right entitles you to subscribe for one (1) new B share.
• Cline has received subscription commitments of approximately SEK 0.58 million, corresponding to approximately 3.4 percent of the Rights Issue, from the Board of Directors, management, clinical advisors and existing shareholders.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8.30 CET on 11 November 2022.

Important Information
The publication, release or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in those jurisdictions where this press release has been published, disclosed or distributed should inform themselves of and observe any such restrictions. This press release does not constitute an offer of, or an invitation to acquire or subscribe for, any securities of Clean Industry Solutions in any jurisdiction.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The information contained in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, South Africa, South Korea or any other jurisdiction where such release, publication or distribution would be contrary to applicable law or regulation.

Within the European Economic Area, no securities are offered to the public in any country other than Sweden.

This press release contains certain forward-looking information that reflects the Company's current views on future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "estimates" and other expressions which imply indications or predictions of future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently subject to known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information is not a guarantee of future performance or development, and actual results may differ materially from those expressed in the forward-looking information.

Cline Scientific AB (publ)Phone: 031-387 55 55

Argongatan 2CEmail: info@clinescientific.com

431 53 MÖLNDAL Website: www.clinescientific.com